GLP-1 tips from a mom creator: what holds up under scrutiny

What did @missusmom actually say?

After losing nearly 100 pounds on semaglutide (Wegovy) and maintaining that loss for three years, she switched to compounded tirzepatide for three months. Her verdict: tirzepatide left her less fatigued, less uncomfortably full, and significantly less constipated. She also mentioned her compounding pharmacy adds vitamin B12 to their formulation, and she plans to continue tirzepatide after January 1st.

She's speaking from genuine long-term GLP-1 experience, not a two-week trial. That context matters when evaluating what she's describing. She's comparing the same person, on two different drugs, across a meaningful time window. That's not nothing.

Does the science back this up?

Mostly yes, with important caveats. The side effect differences she describes are real and documented, though individual variation is enormous.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide works only on GLP-1 receptors. The addition of GIP agonism appears to change the tolerability profile in ways researchers are still working out. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), gastrointestinal side effects with tirzepatide were primarily nausea and diarrhea, not constipation. Constipation rates in SUSTAIN and STEP trials for semaglutide have consistently run higher, around 11-24% depending on dose and population.

The fatigue comparison is less clean. Neither drug lists fatigue as a primary adverse event, but anecdotal reports of energy differences are common in patient communities. There is some mechanistic reasoning here: GIP receptors are expressed in areas involved in energy metabolism, which could plausibly explain differences in how people feel day-to-day. But that's still largely hypothesis territory, not settled science.

What did they get wrong (or right)?

She got the broad strokes right. The constipation difference is the most defensible claim she makes. It tracks with published adverse event profiles. Semaglutide's constipation burden is well-documented, and it was a meaningful enough finding that researchers examined it specifically in the STEP 1 trial data.

The fatigue claim is plausible but unverifiable from her account alone. She had no idea the semaglutide was causing fatigue until she stopped it. That's a reasonable inference, but it could also reflect other variables like diet, sleep, or just the psychological lift of trying something new.

The B12 addition deserves scrutiny. She says her compounding pharmacy adds B12 to the tirzepatide formulation. B12 deficiency can cause fatigue, and GLP-1 medications can reduce food intake enough to affect micronutrient absorption over time. So the B12 might be doing some of the work she's attributing to tirzepatide itself. That's not a trivial confound.

One thing she should not have implied: that compounded tirzepatide is interchangeable with brand-name Zepbound or Mounjaro. It is not. Compounded formulations are not FDA-approved and purity, potency, and bioavailability are not guaranteed to match.

What should you actually know?

The side effect differences between semaglutide and tirzepatide are real but individual. Published data shows tirzepatide users report more nausea and diarrhea, while semaglutide users report more constipation. Neither drug is universally easier to tolerate.

Compounded GLP-1 medications exist in a complicated regulatory space. The FDA has taken enforcement action related to compounded semaglutide and tirzepatide products, and the agency does not consider compounded versions equivalent to their brand-name counterparts. If you are considering compounded GLP-1 medications, the pharmacy's 503B accreditation status matters, and so does working with a licensed prescriber who can monitor your response.

Her experience switching medications to break a maintenance plateau is a real clinical strategy some providers use, but it should happen under medical supervision. The last 20 pounds of a 100-pound weight loss is also, biologically, the hardest stretch, and no medication change guarantees results there.

• Fatigue on GLP-1 medications is underreported in clinical trials but frequently described by patients.
• B12 supplementation in her compounded formulation may have independently affected her energy levels.
• Tolerance differences between semaglutide and tirzepatide vary significantly by individual.